Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Issue 3 (23rd February 2020)

• Record Type: Journal Article
• Authors: Weide, Rudolf; Feiten, Stefan; Chakupurakal, Geothy; Friesenhahn, Vera; Kleboth, Kristina; Köppler, Hubert; Lutschkin, Julia; van Roye, Christoph; Thomalla, Jörg; Heymanns, Jochen
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 3(2020)
• Page Start: 557
• Page End: 566
• Publication Date: 2020-02-23
• Subjects: Chronic lymphocytic leukemia -- CLL -- routine care; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1680840
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Seven hundred and twenty-four CLL-outpatients with a median age of 67 (35–92) were analyzed. Four hundred and twenty-seven (59%) were male, 297 (41%) female. At diagnosis 556 (77%) were in Binet stage A, 91 (13%) stage B and 36 (5%) stage C. Forty-six percent received treatment during the evaluation period. Treatment consisted of purine analogs in 38%, alkylating agents in 96%, chemoimmunotherapy with anti-CD20 monoclonal antibodies in 63%, ibrutinib in 9%, venetoclax in 1% and idelalisib in 3%. 3% received allogeneic hematopoietic stem cell transplantation. Overall survival (OS) according to Binet stage was: A 13.9 years (0.1–37.4), B 9.2 years (1.4–29.3) and C 7.9 years (0.5–19.4) respectively. Median OS from the start of therapy improved over time; 1995–2001: 5.8 years, 2002–2008: 6.1 years and 2009–2017: median not reached. Survival of patients with CLL has improved in routine care and was strongly related to active disease, disease stage, performance status and whether therapy included an anti-CD20 monoclonal antibody.